An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers
Loraine Jarrosson,
Clélia Costechareyre,
Fanny Gallix,
Séverine Ciré,
Fabien Gay,
Olivier Imbaud,
Romain Teinturier,
Elisabetta Marangoni,
Karine Aguéra,
Céline Delloye-Bourgeois,
Valérie Castellani
Affiliations
Loraine Jarrosson
Oncofactory SAS, 8 Avenue Rockefeller, 69008 Lyon, France
Clélia Costechareyre
Oncofactory SAS, 8 Avenue Rockefeller, 69008 Lyon, France
Fanny Gallix
Erytech Pharma, Research and Development Department, 60 Avenue Rockefeller, 69008 Lyon, France
Séverine Ciré
Erytech Pharma, Research and Development Department, 60 Avenue Rockefeller, 69008 Lyon, France
Fabien Gay
Erytech Pharma, Research and Development Department, 60 Avenue Rockefeller, 69008 Lyon, France
Olivier Imbaud
Institut NeuroMyoGène, University of Lyon, University of Lyon 1 Claude Bernard Lyon 1, NeuroMyoGene Institute, CNRS UMR5310, INSERM U1217, 69007 Lyon, France
Romain Teinturier
Oncofactory SAS, 8 Avenue Rockefeller, 69008 Lyon, France
Elisabetta Marangoni
Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005 Paris, France
Karine Aguéra
Erytech Pharma, Research and Development Department, 60 Avenue Rockefeller, 69008 Lyon, France
Céline Delloye-Bourgeois
Oncofactory SAS, 8 Avenue Rockefeller, 69008 Lyon, France; Institut NeuroMyoGène, University of Lyon, University of Lyon 1 Claude Bernard Lyon 1, NeuroMyoGene Institute, CNRS UMR5310, INSERM U1217, 69007 Lyon, France; Corresponding author
Valérie Castellani
Oncofactory SAS, 8 Avenue Rockefeller, 69008 Lyon, France; Institut NeuroMyoGène, University of Lyon, University of Lyon 1 Claude Bernard Lyon 1, NeuroMyoGene Institute, CNRS UMR5310, INSERM U1217, 69007 Lyon, France; Corresponding author
Summary: Lack of preclinical patient-derived xenograft cancer models in which to conduct large-scale molecular studies seriously impairs the development of effective personalized therapies. We report here an in vivo concept consisting of implanting human tumor cells in targeted tissues of an avian embryo, delivering therapeutics, evaluating their efficacy by measuring tumors using light sheet confocal microscopy, and conducting large-scale RNA-seq analysis to characterize therapeutic-induced changes in gene expression. The model was established to recapitulate triple-negative breast cancer (TNBC) and validated using TNBC standards of care and an investigational therapeutic agent.